Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-09-12
2006-09-12
Davis, Brian (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S292000, C424S193100, C424S201100
Reexamination Certificate
active
07105574
ABSTRACT:
The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.
REFERENCES:
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5910488 (1999-06-01), Nabel et al.
patent: 5994317 (1999-11-01), Wheeler
patent: 6022874 (2000-02-01), Wheeler
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6235310 (2001-05-01), Wang et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6586409 (2003-07-01), Wheeler
patent: 6670332 (2003-12-01), Wheeler
patent: 6696424 (2004-02-01), Wheeler
patent: 6706694 (2004-03-01), Wolff et al.
patent: 2002/0019358 (2002-02-01), Manthorpe et al.
patent: 2003/0032615 (2003-02-01), Felgner et al.
patent: 2003/0091544 (2003-05-01), Parker et al.
patent: 2003/0186913 (2003-10-01), Wolff et al.
patent: 2003/0191082 (2003-10-01), Wheeler
patent: 2003/0203863 (2003-10-01), Hobart et al.
patent: 2004/0157789 (2004-08-01), Geall et al.
patent: 2004/0162256 (2004-08-01), Geall et al.
patent: 2004/0171572 (2004-09-01), Wheeler
patent: 2004/0209241 (2004-10-01), Hermanson et al.
patent: WO 94/29469 (1994-12-01), None
patent: WO 97/19675 (1997-06-01), None
patent: WO 00/57917 (2000-10-01), None
Abbas, A.K. et al., “Functional diversity of helper T lymphocytes,”Nature 383:787-793, Macmillan Journals Ltd. (1996).
Barnfield, C., et al., “The Cellular Basis of Immune Induction at Mucosal Surfaces by DNA Vaccination,”International Conference: Development and Clinical Progress of DNA Vaccines,p. 28b (Oct. 1999).
Barnfield, C. et al., “The Cellular Basis of Immune Induction at Mucosal Surfaces by DNA Vaccination,”Developments in Biological Standardization, vol. 104, Development and Clincal Progress of DNA Vaccines,Brown, F., et al., eds., Basel, Karger, pp. 159-164 (Jul. 2000).
DeBruyne, L.A., et al., “Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses,”Gene Ther. 5:1079-1087 (Aug. 1998).
Donnelly, J.J., et al., “Adjuvant Effects of DNA Vaccines,” inVaccines 97,Cold Spring Harbor Laboratory Press, pp. 105-111 (1997).
D'Souza, S. et al., “Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids,”Infect. Immun. 70:3681-3688, American Soicety for Microbiology (Jul. 2002).
Etchart, N. et al., “Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin,”J. Gen. Virol. 78:1577-1580, Society of General Microbiology (1997).
Felgner, P.L. et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA 84:7413-7417, The National Academy of Sciences of the United States of America (1987).
Felgner, J.H. et al., “Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations”J. Biol. Chem. 269:2550-2561, The American Soicety for Biochemistry and Molecular Biology, Inc. (1994).
Felgner, P.L., “Nonviral Strategies for Gene Therapy,”Sci. Am. 276:102-106, Scientific American, Inc. (1997).
Fox, J.L., “No winners against AIDS,”Bio/Technology 12:128, Nature Publishing Co. (1994).
Golding, B. et al., “The Potential for Recruiting Immune Responses Toward Type 1 or Type 2 T Cell Help,”Am. J. Trop. Med. Hyg. 50:33-40, The American Society of Tropical Medicine and Hygiene (1994).
Gramzinski, R.A. et al., “Immune Response to a Hepatitis B DNA Vaccine in Aotus Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration,”Mol. Med. 4:109-118, The Picower Institute Press (Feb. 1998).
Gregoriadis, G. et al., “Liposome-mediated DNA vaccination,”FEBS Lett. 402:107-110, Elsevier Science B.V. (1997).
Ishii, N. et al., “Cationic Liposomes Are a Strong Adjuvant for a DNA Vaccine of Human Immunodeficiency Virus Type 1,”AIDS Res. Hum. Retroviruses 13:1421-1428, Mary Ann Liebert, Inc. (1997).
Klavinskis, L.S. et al., “Mucosal immunization with DNA-liposome complexes,”Vaccine 15:818-820, Elsevier Science Ltd. (1997).
Klavinskis, L.S., et al., “Intranasal Immunization with Plasmid DNA-Lipid Complexes Elicits Mucosal Immunity in the Female Genital and Rectal Tracts,”J. Immunol. 162:254-262, American Association of Immunologists (Jan. 1999).
“C35H71N2O2,”Chem. Abstracts 133(Formula Index):5164F,American Chemical Society(Dec. 2000).
Norman, J.A. et al., “Development of improved vectors for DNA-based immunization and other gene therapy applications,”Vaccine 15:801-803, Elsevier Science Ltd. (1997).
Norman, J. et al., “Adjuvants for Plasmid DNA Vaccines,” inMethods in Molecular Medicine, vol. 29, DNA Vaccines: Methods and Protocols,Lowrie, D.B. and R.G. Whalen, eds., Humana Press Inc., Totowa, NJ, pp. 185-196 (Aug. 1999).
Okada, E. et al., “Intranasal Immunization of a DNA Vaccine with IL-12- and Granulocyte- Macrophage Colony-Stimulating Factor (GM-CSF)-Expressing Plasmids in Liposomes Induces Strong Mucosal and Cell-Mediated Immune Responses Against HIV-1 Antigens,”J. Immunol. 159:3638-3647, American Association of Immunologists (1997).
Parker, S. et al., “Tissue Distribution of the Cytofectin Component of a Plasmid-DNA/Cationic Lipid Complex Following Intravenous Administration in Mice,”Hum. Gene Ther. 8:393-401, Mary Ann Liebert, Inc. (1997).
Raz, E. et al., “Preferential induction of a Th1immune response and inhibtion of specific IgE antibody formation by plasmid DNA immunization,”Proc. Natl. Acad. Sci. USA 93:5141-5145, The National Academy of Sciences of the United States of America (1996).
Sankar, V. et al., “Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses,”Oral Dis 8:275-281, Blackwell Munksgaard (Nov. 2002).
Stephan, D.J. et al., “A New Cationic Liposome DNA Complex Enhances the Efficiency of Arterial Gene Transfer In Vivo,”Hum. Gene Ther. 7:1803-1812, Mary Ann Liebert, Inc. (1996).
Ulmer, J.B. et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,”Science 259:1745-1749, American Association for the Advancement of Science (1993).
Wheeler, C.J. et al., “A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung,”Proc. Natl. Acad. Sci. USA 93:11454-11459, The National Academy of Sciences of the United States of America (1996).
Wheeler, C.J. et al.,. “Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes,”Biochimica et Biophysica Acta 1280:1-11, Elsevier Science B.V. (1996).
Wheeler, C.J., “Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines,”Chem. Abstracts 133:636-637, Abs. No. 133:280556a, American Chemical Society (Nov. 2000).
Yasutomi, Y. et al., “A Vaccine-Elicited, Single Viral Epitope-Specific Cytotoxic T Lymphocyte Response Does Not Protect against Intravenous, Cell-Free Simian Immunodeficiency Virus Challenge,”J. Virol. 69:2279-2284, American Society for Microbiology (1995).
Yokoyama, M. et al., “DNA immunization: Effects of vehicle and route of administration on the induction of protective antiviral immunity,”FEMS
Davis Brian
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
LandOfFree
Adjuvant compositions and methods for enhancing immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant compositions and methods for enhancing immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant compositions and methods for enhancing immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587347